Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-02-04
2010-02-02
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S064000, C536S023500, C530S350000
Reexamination Certificate
active
07655402
ABSTRACT:
Methods and compositions for treating and diagnosing cancer and screening for agents for such treatment and diagnosis are provided. The methods involve screening for agents that modulate the activity or expression of FOXM1, which has been discovered herein to play a role in cell growth and cell cycle regulation. Methods for treating cancer, methods for modulating the activity or expression of FOXM1, methods for diagnosing a subject that has or is at risk of developing cancer, and pharmaceutical compositions are also provided.
REFERENCES:
patent: WO-99/32619 (1999-07-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/63364 (2000-10-01), None
patent: WO-01/75164 (2001-10-01), None
patent: WO-01/92513 (2001-12-01), None
patent: WO-02/061134 (2002-08-01), None
patent: WO-02/092013 (2002-11-01), None
Kim et al. (J. Biol. Chem. Jun 10, 2005; 280 (23): 22278-22286).
Yoshida et al. (Gastroenterol. 2007; 132: 1420-1431).
De Plaen et al. (Immunogenetics. 1994; 40: 360-369).
Ward (Developmental Oncology 1985; 21: 91-106).
Rae et al. (International Journal of Cancer. 2000; 88: 726-732).
Tockman et at (Cancer Research 1992; 52: 2711s-2718s).
Chen et al. (Mol. Cell. Proteomics. Apr. 2002; 1 (4): 304-313).
Liu et al. (Cancer J. Sep.-Oct. 2001; 7 (5): 395-403).
Lichtinghagen et al. (Eur. Urol. 2002; 42 (4): 398-406).
Roessler et al. (Mol. Cell. Prot. 2006; 5 (11): 2092-2101).
Zolg et al. (Mol. Cell. Prot. 2004; 3 (4): 345-354).
Altieri, “Validating Survivin as a Cancer Therapeutic Target” Nat. Rev. Cancer 3: 46-54 (2003).
Ausubel et al., “Hybridization Analysis of DNA Blots” Current Protocols in Molecular Biology, §§ 2.10, 6.3-6.4, John Wiley & Sons, Inc. (1995).
Brown et al., “ATR Disruption Leads to Chromosomal Fragmentation and Early Embryonic Lethality” Genes and Development, 14: 397-402 (2000).
Brummelkamp et al., “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells” Science, 296: 550-553 (2002).
Chan et al., “14-3-3Sigma is Required to Prevent Mitotic Catastrophe After DNA Damage” Nature, 401: 616-620 (1999).
DeLuca et al., “hNuf2 Inhibition Blocks Stable Kinetochore-Microtubule Attachment and Induces Mitotic Cell Death in HeLa Cells” Journal of Cell Biology, 159(4): 549-555 (2002).
Dimri et al., “A Biomarker That Identifies Senescent Human Cells in Culture and in Aging Skin in Vivo” Proc Natl Acad Sci USA, 92:9363-9367 (1995).
Dutertre et al., “Phosphorylation of CDC25B by Aurora-A at the Centrosome Contributes to the G2-M Transition” Journal of Cell Science, 117: 2523-2531 (2004).
Elbashir et al., “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells” Nature, 411:494-498 (2001).
Elbashir et al., “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs” Genes and Development, 15:188-200 (2001).
Faragher et al., “Nek2A Kinase Stimulates Centrosome Disjunction and is Required for Formation of Bipolar Mitotic Spindles” Molecular Biology of the Cell, 14:2876-2889 (2003).
Fontijn at al., “The Human Kinesin-Like Protein RB6K is Under Tight Cell Cycle Control and is Essential for Cytokinesis” Molecular and Cellular Biology, 21(8): 2944-2955 (2001).
Fry at al., “A Centrosomal Function for the Human Nek2 Protein Kinase, a Member of the NIMA Family of Cell Cycle Regulators” EMBO Journal 17(2): 470-481 (1998).
Goshima et al., “Human Centromere Chromatin Protein hMisI2, Essential for Equal Segregation, is Independent of CENP-A Loading Pathway” Journal of Cell Biology 160(1): 25-39 (2003).
Grossman et al., “Inhibition of Melanoma Tumor Growth in Vivo by Survivin Targeting” Proc Natl Acad Sci USA 98(2): 635-640 (2001).
Gyuris et al., “Cdi1, a Human G1 and S Phase Protein Phosphatase that Associates with Cdk2” Cell, 75:791-803 (1993).
Hill et al., “Evaluation of Normalization Procedures for Oligonucleotide Array Data Based on Spiked cRNA Controls” Genome Biology, 2(12): RESEARCH0055.1-0055.13 (2001).
Hinchcliffe et al., “Requirement of a Centrosomal Activity for Cell Cycle Progression Through G1 into S phase” Science, 291:1547-1550 (2001).
Hinchcliffe et al., “It takes two to tango”; understanding how centrosome duplication is regulated throughout the cell cycle, Genes and Development, 15: 1167-1181 (2001).
Howman et al., “Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice” Proc Natl Acad Sci USA, 97(3):1148-1153 (2000).
Kalinichenko at al., “Differential expression of forkhead box transcription factors following butylated hydroxytoluene lung injury” Am. J. Physiol. Lung Cell Mol. Physiol., 280:L695-L704 (2001).
Kalinichenko et al., “Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor”, Genes and Development, 18:830-850 (2004).
Kawasaki at al., “Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer”, Cancer Research, 58:5071-5074 (1998).
Khodjakov et al., “Centrosomes enhance the fidelity of cytokinesis in vertebrates and are required for cell cycle progression”, Journal of Cell Biology, 153(1): 237-242 (2001).
Korver at al., “The winged-helix transcription factor Trident is expressed in cycling cells” Nucleic Acids Research, 25(9): 1715-1719 (1997).
Korver et al., “Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident”, Current Biology Ltd., 8:1327-1330 (1998).
Lai et al., “RBP1 induces growth arrest by repression of E2F-dependent transcription” ncogene 18: 2091-2100 (1999).
Lee et al., “Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression”, Molecular and Cellular Biology, 20(5): 1723-1732 (2000).
Leung et al., “Over-expression of FoxM1 stimulates cyclin B1 expression”, FEBS Letters, 507:59-66 (2001).
Li et al., “Pleiotropic cell-division defects and apoptosis induced by interference with survivin function”, Nature Cell Biology, 1: 461-466 (1999).
Liang et al., “Mitotic cell death in BEL-7402 cells induced by enediyne antibiotic lidamycin is associated with centrosome overduplication”, World J Gastroenterol, 10(18): 2632-2636 (2004).
Lingle et al., “Centrosome amplification drives chromosomal instability in breast tumor development” Proc Natl Acad Sci USA, 99(4): 1978-1983 (2002).
Lockhart et al., “Expression monitoring by hybridization to high-density oligonucleotide arrays”, Nature Biotechnology, 14: 1675-1680 (1996).
Margottin-Goguet et al., “Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase”, Developmental Cell 4: 813-826 (2003).
Meraldi et al., “Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells”, EMBO Journal, 21(4): 483-492 (2002).
Meraldi et al., “Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A” Nature Cell Biology, 1: 88-93 (1999).
Monzo et al., “A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers”, Journal of Clinical Oncology, 17(7): 2100-2104 (1999).
Nakayama et al., “Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication”, EMBO Journal, 19(9): 2069-2081(2000).
Nitta et al., “Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents”, Oncogene, 23: 6548-6558 (2004).
Follettie Maximillian T.
Wonsey Diane R.
Rawlings Stephen L
Wyeth LLC
Zahner Joseph E.
LandOfFree
Diagnoses and therapeutics for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnoses and therapeutics for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnoses and therapeutics for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152778